Welcome to our dedicated page for Surgalign Holdings news (Ticker: SRGA), a resource for investors and traders seeking the latest updates and insights on Surgalign Holdings stock.
Surgalign Holdings, Inc. (SRGA) is a prominent medical technology company that specializes in the design, development, manufacture, and distribution of biologic, metal, and synthetic implants worldwide. Established in 1997 and headquartered in Deerfield, Illinois, Surgalign Holdings has carved out a significant niche in the fields of orthopedics, spine, sports medicine, plastic surgery, trauma, and other surgical procedures.
The company offers a range of innovative products aimed at improving surgical outcomes and promoting natural healing. Among its key offerings is the Coflex Interlaminar Stabilization Device, which is designed to treat moderate to severe lumbar spinal stenosis in conjunction with decompression. Additionally, the Simmetry Sacroiliac Joint Fusion System is known to decrease opioid use, pain, and disability. Another notable product is the Fortilink IBF System with TETRAfuse 3D technology, enhancing the integration and fusion of spinal implants.
Surgalign’s state-of-the-art implants are utilized by healthcare providers, hospitals, and various healthcare facilities through a robust distribution network. The company leverages its direct distribution force, OEM relationships, and an extensive network of independent distributors to reach its clients effectively. Surgalign's commitment to quality and innovation has positioned it as a leader in medical technology, dedicated to enhancing patient outcomes and advancing the field of surgical implants.
For more information, the latest updates, and media inquiries, please contact Glenn Wiener at gwiener@gwcco.com or +1 917 887 8434.
Surgalign Spine Technologies (NASDAQ: SRGA) reported first-quarter 2021 results with global spine revenue of $23.3 million, down from $27.1 million in Q1 2020. The company experienced a net loss from continuing operations of $15.2 million, which includes $3.2 million in non-recurring charges. Adjusted EBITDA loss improved to $9.8 million from $20.1 million year-over-year. Surgalign appointed Marc Mackey as Executive VP, Digital Surgery, and filed a 510(k) for the Holo Surgical intelligent guidance system, a key milestone for the year.
Surgalign Spine Technologies (NASDAQ: SRGA) announced the submission of a premarket notification 510(k) to the FDA for its innovative digital surgical guidance system. This system integrates augmented reality (AR) and artificial intelligence (AI) to provide real-time surgical guidance, enhancing accuracy in spinal surgeries. Developed over six years, this system allows surgeons to visualize patient-specific anatomy during procedures. The company aims to improve the efficiency of over 1.5 million annual instrumented spinal surgeries in the U.S. with this ground-breaking technology.
Surgalign Spine Technologies (NASDAQ: SRGA) has acquired a medical device machine shop to enhance its Spine Innovation Center in San Diego. The acquisition aims to streamline research and development by integrating advanced prototyping and manufacturing capabilities. This move is projected to shorten product development timelines and improve quality control. Surgalign's President, Terry Rich, expressed confidence that this will lead to superior products and better customer solutions, reinforcing the company’s commitment to advancing digital surgery in spine care.
Surgalign Spine Technologies (NASDAQ: SRGA) announced it will release its first quarter 2021 financial results on May 10, 2021, after the market closes. The company will hold a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can access the call by calling (877) 383-7419 or visiting Surgalign's investor website. The conference call replay will be available for one month. Surgalign focuses on advancing digital surgery technologies aimed at improving surgical outcomes globally.
Surgalign Spine Technologies (NASDAQ: SRGA) appointed Marc Mackey as Executive Vice President of Digital Surgery, effective immediately. Mackey, who has over 25 years of experience in orthopedic and surgical technology, will lead efforts to develop digital surgery solutions. His role involves managing the Digital Surgery Team, formed after Surgalign's acquisition of Holo Surgical in 2020. The company aims to redefine surgical practices using technology to enhance patient outcomes. CEO Terry Rich emphasized the need for experienced leadership to advance digital surgery initiatives.
Surgalign Holdings, Inc. (Nasdaq: SRGA), a leader in medical technology, is set to present at the Sidoti Virtual Investor Conference on March 25, 2021, at 10:45 a.m. Eastern Time. The presentation will highlight the company’s commitment to advancing spine surgery and enhancing patient outcomes through digital technology. Attendees can access a live audio webcast on Surgalign's investor relations page, with a replay available later. The company, headquartered in Deerfield, IL, operates worldwide and focuses on delivering innovative spine care solutions.
Surgalign Holdings, Inc. (Nasdaq: SRGA) reported Q4 2020 results with global spine revenue at $26.2 million, down from $31.6 million year-over-year, primarily due to COVID-19 impacts. The company incurred a net loss of $118 million, which included $101 million in non-recurring charges. Adjusted EBITDA loss was $7.7 million, showing improvement from the previous year's loss. The company completed a $40 million equity financing in Q1 2021 and anticipates 7-10% revenue growth for 2021, assuming a return to normal procedure volumes.
Surgalign Holdings, Inc. (Nasdaq: SRGA) announced a change in its earnings release date for the fourth quarter and full year 2020 due to delays in completing financial statements related to the OEM business sale. The new release date is set for March 16, 2021, post-market close. A conference call will follow at 4:30 p.m. ET, accessible via phone and webcast. Surgalign focuses on innovative spine care solutions, aiming to enhance surgical outcomes and improve patient lives.
Surgalign Holdings, Inc. (Nasdaq: SRGA) announced plans to release its financial results for Q4 and the full year 2020 on March 11, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET that day, accessible via U.S. and international dialing options. The company focuses on spine surgery advancements and improving patient outcomes through digital technology. It operates in over 50 countries, driven by a commitment to clinical innovation. Interested parties can access the conference call via the investor section of Surgalign's website.
Surgalign Holdings, Inc. (Nasdaq: SRGA) has announced its 2021 Annual Meeting of Stockholders will occur virtually on May 4, 2021, at 9:00 A.M. Central Time. Stockholders of record by March 15, 2021, can vote on meeting matters. Proposals for the meeting must be submitted by February 22, 2021, per SEC regulations. Proxy materials will be mailed around March 30, 2021. The company focuses on innovative solutions in spine care to improve surgical outcomes, distributing products across the U.S. and over 40 countries.
FAQ
What does Surgalign Holdings, Inc. specialize in?
Where is Surgalign Holdings, Inc. headquartered?
What are some key products offered by Surgalign Holdings, Inc.?
How does Surgalign distribute its products?
In which medical fields are Surgalign’s implants used?
When was Surgalign Holdings, Inc. founded?
What is the purpose of the Coflex Interlaminar Stabilization Device?
How does the Simmetry Sacroiliac Joint Fusion System benefit patients?
What technology does the Fortilink IBF System utilize?
Who should be contacted for media inquiries about Surgalign Holdings, Inc.?
